Brazil CMO/CDMO Business to Reach US$ 907.67 Million by 2033 as Demand for Regional Pharmaceutical Production Expands | Future Market Insights, Inc.
In recent years, there has been a notable surge in the growth of the CMO and CDMO sectors. The pharmaceutical and biotechnology industries, recognizing the benefits of cost efficiency, adaptability, and access to specialized expertise, have increasingly turned to outsourcing for their production and development services.
NEWARK, Del, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The Brazil CMO/CDMO business industry is projected to increase *US$ 697.93 million* in 2023. It is anticipated to exhibit a *CAGR* of *2.7%* over the forecast period (2023 to 2033). The business is set to attain a valuation of around *US$ 907.67 million* by 2033.The contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) space in Brazil is a dynamic and rapidly evolving sector in the pharmaceutical and biotechnology businesses. Brazil, one of the leading pharmaceutical ecosystems in Latin America, offers significant opportunities and challenges for CMOs and CDMOs.
*Request A Sample Copy of This Report:* https://www.futuremarketinsights.com/reports/sample/rep-gb-18061
The pharmaceutical sector in Brazil has been expanding rapidly in recent years, driven by factors such as an aging population, increased healthcare access, and a growing middle class. This growth has translated into a rising demand for pharmaceutical products and manufacturing services, making Brazil an attractive destination for CMOs and CDMOs.
The Brazilian Health Regulatory Agency (ANVISA) enforces strict regulatory standards for pharmaceutical manufacturing. CMOs and CDMOs that can navigate and assist clients in meeting these regulatory requirements gain a competitive advantage in the business.
To operate effectively in Brazil, pharmaceutical companies are often required to have a local manufacturing presence. This has led to collaborations and partnerships with local CMOs and CDMOs, both domestic and international.
Brazil's pharmaceutical landscape is increasingly focusing on biotechnology, including the development of biologics, biosimilars, and advanced therapies. CMOs and CDMOs with expertise in biomanufacturing are well-positioned to cater to this growing segment.
*Key Takeaways from the Brazil CMO/CDMO Business Study:*
· By service, the stand-alone service segment is expected to hold a share of *46.2%* and surge at a CAGR of *3.4%* by 2033.
· By product, the API substrate segment is anticipated to showcase a lucrative CAGR of *1.9%* from 2023 to 2033.
· By expression system, the mammalian segment will likely exhibit a CAGR of *2.7%* in the estimated period.
· By company size, the mid-sized companies segment is anticipated to record a CAGR of *2.3%* in the evaluation period.
· By the scale of operation, the commercial segment is estimated to register a CAGR of *2.9%* from 2023 to 2033.
· Southeast Brazil is considered to be the leading region with a value share of *68.6%* at the end of the forecast period.
*“With rising drug development complexity, specializing in specific therapeutic areas, and high-quality manufacturing, the Brazil CMO/CDMO business is expected to witness an advancement over the forecast period,” **opines *Sabyasachi Ghosh* Associate Vice President at Future Market Insights (FMI).*
*Brazil CMO/CDMO Business Report Scope:*
*Attribute* *Details*
*Brazil CMO-CDMO Revenue (2022)* US$ 679.10 million
*Projected Brazil CMO-CDMO Revenue (2033)* US$ 907.67 million
*Value-based CAGR (2023 to 2033)* 2.7%
*Forecast Period* 2023 to 2033
*Historical Data Available for* 2018 to 2022
*Business Analysis* Value (US$ million)
*Key Regions Covered* North Brazil, Northeast Brazil, Central-west Brazil, Southeast Brazil, and South Brazil
*Key Segments Covered* · Services
· Product
· Expression System
· Company Size
· Scale of Operation
· Region
*Key Companies Profiled* · Lonza AG
· Unither Pharmaceuticals
· Catalent Inc.
· Fagron
· Eurofarma
· Pfizer CentreOne
· Patheon N.V. (Thermo Fisher Scientific, Inc.)
· NUVISAN
· Societal CDMO
· Bio-Manguinhos
· Biotimize
· Pierre Fabre group
· Ajinomoto Co., Inc.
*
*
*Act Now to Explore In-Depth Market Analysis: Get an Exclusive Discount Now to Access Industry Trends: *https://www.futuremarketinsights.com/checkout/18061
*Competitive Landscape:*
Expansion and acquisition among leading companies or brands is the key strategy of manufacturers of the ecosystem, such as Catalent and Fragon, among others. They aim to enhance their presence in the business and compete with other firms during the forecast period. Following are a few examples of the latest developments:
· *In February 2022,* Pharma Nobis, LLC completed its acquisition of Fagron’s contract manufacturing business and manufacturing facility.
· *In August 2022,* Catalent made an announcement regarding its acquisition of Metrics Contract Services. Metrics Contract Services is a specialized Contract Development and Manufacturing Organization (CDMO) known for its 333,000-square-foot facility located in Greenville.
*Brazil CMO/CDMO Industry Outlook by Category:*
*By Services:*
· Stand-alone Services
· Cell Line Development
· Development and Bio Manufacturing
· Analytical Services
· Fill Finish
· Packaging
· Clinical Supply Services
· Integrated Development
· Scale-up and Tech Transfer
· Technology and Innovation
· Quality Control and Quality Assurance
· Regulatory Assistance
*By Product:*
· API Substrate
· Large Molecule
· Monoclonal Antibodies
· Antibody Fragments
· Recombinant Therapeutic Proteins
· Viral Vector
· Cell and Gene Therapy
· Vaccine
· Peptides
· Antibody Drug Conjugates (ADCs)
· Small Molecule*By Expression System:*
· Mammalian
· Microbial
· Bacteria
· Yeast
*By Company Size:*
· Small
· Mid-sized
· Large
· Very Large
*By Scale of Operation:*
· Preclinical
· Clinical
· Phase I
· Phase II
· Phase III
· Commercial
*Author By:*
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
*Explore FMI’s related ongoing Coverage in the **Healthcare Market Insights** Domain:*
CMO/CDMO Market Size: The global CMO/CDMO market is estimated to be valued at US$ 22.5 billion in 2023. The market is projected to reach US$ 39.4 billion by 2033, exhibiting a CAGR of 5.7% from 2023 to 2033.
Small Molecule CMO/CDMO Market Share: According to Future Market Insights research, during the projected period, the global small molecule CMO/CDMO market is expected to grow at a CAGR of 5.2%. The market value is projected to increase from US$ 74,998.1 million in 2024 to US$ 124,532.4 million by 2034.
Expectorant Drugs Market Demand: The expectorant drugs market is projected to generate US$ 17,648.2 million in 2024. expectorant drugs market revenue is predicted to reach US$ 38,455.4 million by 2034. A CAGR of 4.3% is expected for the expectorant drugs market during the forecast period.
ECG Machine Market Growth: The global ECG machine market size is projected to surpass a valuation of US$ 15,725.60 million in 2034. As per the analysis, the ECG machine market is likely to exhibit a CAGR of 7.2% through 2034, with a current valuation of US$ 7,833.5 million in 2024.
Digital Scale Market Trends: The global digital scale market is expected to rise at a CAGR of 4.5% through 2034. The market value is projected to increase from US$ 564.6 million in 2024 to US$ 877.1 million by 2034.
*About Future Market Insights (FMI) *
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
*Contact Us: *
Nandini Singh Sawlani* *
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
*For Sales Enquiries: *sales@futuremarketinsights.com
*Website:* https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube